Jim Cramer and Wall Street Are Bullish on Fair Isaac Corporation (FICO)
We recently published a list of 10 Stocks on Jim Cramer and Wall Street’s Radar.
Insider Monkey Blog
Jim Cramer and Wall Street Are Bullish on Capital One Financial Corporation (NYSE:COF)
We recently published a list of 10 Stocks on Jim Cramer and Wall Street’s Radar.
Jim Cramer and Wall Street Are Watching UnitedHealth Group (UNH)
We recently published a list of 10 Stocks on Jim Cramer and Wall Street’s Radar.
RBC Capital Markets Downgrades Civitas Resources (CIVI) Stock, Reduces PT
RBC Capital analyst Scott Hanold downgraded Civitas Resources, Inc.
Truist Downgrades Airbnb (ABNB) Stock to Sell, Reduces PT
On May 30, Truist Securities downgraded Airbnb, Inc.
Wolfe Research Initiates Coverage of Beta Bionics (BBNX) Stock with Outperform Rating
As per the analyst, the insulin pumps are a double-digit growth category, with the company taking share from the low base. The firm believes that Beta Bionics, Inc.
BofA Resumes Coverage of CoStar Group (CSGP) Stock with Neutral Rating
On May 30, BofA Securities resumed coverage on CoStar Group, Inc. (NASDAQ:CSGP)’s stock with a “Neutral” rating and a price objective of $79.00.
Telsey Advisory Reduces PT on Burlington Stores (BURL) Stock, Maintains Outperform Rating
On May 30, Telsey Advisory Group reduced its price objective on Burlington Stores, Inc.
KeyBanc Raises C3.ai (AI) Price Target, Keeps Underweight Rating
On Thursday, May 29, KeyBanc Capital Markets raised the price target for C3.ai, Inc. (NYSE:AI) from $17 to $18 and kept an “Underweight” rating.
Citi Raises Price Target for Abercrombie & Fitch (ANF), Keeps Buy Rating
On Thursday, May 29, Citi analyst Paul Lejeuz raised the price target for Abercrombie & Fitch Co. (NYSE:ANF) from $98 to $105 and kept a “Buy” rating.
Morgan Stanley Raises Unity Software (U) Price Target, Keeps Rating
On Friday, May 30, Morgan Stanley raised the price target for Unity Software Inc. (NYSE:U) from $12 to $15 and kept an “Equal-Weight” rating.
UBS Lowers Dell Technologies (DELL) Price Target, Keeps Buy Rating
On Friday, May 30, UBS analyst David Vogt lowered the price target for Dell Technologies Inc. (NYSE:DELL) from $150 to $145 and reiterated a “Buy” rating.
These 10 Stocks Just Rocked The Market
Ten companies posted a sluggish performance last week, with investor sentiment weighed down by a wave of negative developments, including disappointing earnings performance, not...
Jim Cramer on D-Wave Quantum (QBTS): “Of the Ones That Are Out There, This is the Best”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where D-Wave Quantum Inc.
Jim Cramer on BigBear.ai Holdings (BBAI): “I’m Going to Suggest Palantir”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where BigBear.ai Holdings, Inc.
Jim Cramer on The Wendy’s Company (WEN): “I’m Reiterating My Get Out of Wendy’s Call”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks.
Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where Biohaven Ltd.
Jim Cramer Says Buy DICK’S Sporting Goods (DKS) Sporting Goods”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where DICK’S Sporting Goods, Inc.
Jim Cramer on IDEXX Laboratories, Inc. (IDXX): “I Just Can’t Get My Arms Around It”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where IDEXX Laboratories, Inc.
Jim Cramer on Verizon Communications Inc. (VZ): “They’re Doing Better”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where Verizon Communications Inc.
Jim Cramer Notes “You Have a Winner in AutoZone (AZO)”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where AutoZone, Inc.
Jim Cramer on NIKE, Inc. (NKE): “There’s a Good Chance for a Comeback”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at where NIKE, Inc.
Jim Cramer Says “NVIDIA (NVDA) Could Cede Its Crown to China”
We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks.
Black Spade Acquisition II Co (BSII) Steps Closer to Merger Completion with Shareholders’ Approval
Shareholders of Black Spade Acquisition II Co (NASDAQ:BSII) have approved the proposed business combination with The Generation Essentials Group (TGE), moving the deal a step ...
GIBO Holdings Limited (GIBO) Unveils SparkRWA to Merge IP Tokenization and Asset Verification
GIBO Holdings Limited (NASDAQ:GIBO) has launched SparkRWA, a two-in-one platform that allows creators to tokenize narrative concepts and authenticate real-world artistic assets...
Grindr Inc. (GRND)’s Right Now Feature goes Global
Grindr Inc. (NYSE:GRND) has officially launched its real-time discovery tool, Right Now, across all global markets.
Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial
Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy...
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results
Regeneron Pharmaceuticals, Inc.
Gilead Sciences, Inc, (GILD)’s Trodelvy and Merck & Co., Inc, (MRK)’s Keytruda Cuts Breast Cancer Progression Risk by 35%
A new clinical trial has shown that combining Gilead Sciences, Inc. (NASDAQ:GILD)’s Trodelvy with Merck & Co., Inc.
BeOne Medicines Ltd. (ONC)’s Combo Drug Shows Strong CLL Response
BeOne Medicines Ltd.
Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial
Xilio Therapeutics, Inc.
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis
Vancouver-based biotech firm AbCellera Biologics Inc. (NASDAQ:ABCL) has announced a major milestone in its fight against atopic dermatitis (AD).
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is set to unveil results from its Phase 1 clinical trial of KT-621, a first-in-class oral STAT6 degrader, on Monday, June 2, 2025.
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial
Perspective Therapeutics, Inc.
15 Best Large Cap Energy Stocks to Buy According to Hedge Funds
Though the overall energy industry has fallen by over 6.4% so far this year, thanks in large part to the plunge in crude oil prices and the prospects of a global economic slowdown...
China Likely “Not Off the Map” for NVDA, Longtime Investor Says
Nvidia Corporation (NASDAQ:NVDA) still has "an opportunity in China," and "many think" that the chip giant will be able to sell modified chips to the Asian country in the not-...
Wells Fargo Maintains Underweight Rating on Ally Financial (ALLY) Stock
Wells Fargo analyst Donald Fandetti maintained an Underweight rating on Ally Financial Inc. (NYSE:ALLY) with a $32 price target.
BofA Slashes Cooper Companies (COO) Price Target to $96, Keeps Buy Rating
On May 30, BofA analyst Craig Bijou reiterated a Buy rating on Cooper Companies, Inc. (NASDAQ:COO), lowering the associated price target to $96.00 from $120.00.
Goldman Sachs Upgrades First Solar Price Target to $255
Brian Lee, the firm’s analyst, stated that the revised 12-month price target prices a higher P/E multiple applied to their EPS forecasts over the next four quarters.
Cooper Companies (COO) Gets Buy Rating From William Blair Following Q2 Report
On May 30, William Blair analyst Margaret Kaczor maintained a bullish stance on Cooper Companies, Inc.
JPMorgan Downgrades Cooper Companies (COO) to Neutral, Cuts PT
On May 30, JPMorgan downgraded Cooper Companies, Inc. (NASDAQ:COO) to Neutral from Overweight and slashed the price target to $76 from $110.
Jefferies Remains Bullish on Marvell Technology (MRVL) Following Q1 Report
On May 30, Jefferies analyst Blayne Curtis maintained a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with a $90.00 price target.
Axon Enterprise (AXON) Gets Price Target Hike on Strong Growth Outlook
On May 29, TD Cowen reiterated its bullish review of Axon Enterprise Inc. (NASDAQ:AXON), raising the price target from $750 to $800 while keeping the stock's rating at Buy.
KeyCorp Gets Steady Target From KBW Despite Slight Dip in Investment Banking Growth
With a stable price target of $18, analyst David Konrad of Keefe, Bruyette & Woods kept his Outperform rating on KeyCorp (NYSE:KEY) on May 29.
Citi Reiterates Buy on Knight-Swift (KNX), Raises Price Target Amid Freight Optimism
Ariel Rosa of Citi revised the firm's outlook on Knight-Swift Transportation Holdings Inc. (NYSE:KNX) on May 30.
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval
On May 30, BTIG analysts reaffirmed their Buy rating and $99 price target for Alcon Inc.
Sempra Price Target Lifted by Jefferies Despite Lowered Guidance
Julian Dumoulin-Smith, an analyst at Jefferies, revised his outlook for Sempra (NYSE:SRE), increasing the price target from $75 to $78 while keeping the stock at a Hold rating...
Hedge Fund Resource Center
